Novel compounds as potential anti-dengue therapies verified via inhibition of human hexokinase isoform II
Dengue is one of the most fatal diseases in the world, which is caused by dengue virus (DENV). It has been reported that a glycolytic enzyme, namely the human hexokinase II (HKII) has a significant role in supporting viral replication in the host cell, thus the enzyme has been proposed as a drug t...
Saved in:
Main Authors: | Tanbin, Suriyea, Ahmad Fuad, Fazia Adyani |
---|---|
Format: | Conference or Workshop Item |
Language: | English |
Published: |
2020
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/87156/1/iRep_KERICE2020_updated-KERICE%202020%20abstract%20compilation.pdf http://irep.iium.edu.my/87156/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Interrogating novel compounds for improved anti-dengue therapies via inhibition of human hexokinase II (HKII)
by: Ahmad Fuad, Fazia Adyani, et al.
Published: (2020) -
Effects of Daidzin and analogue of Ganoderma sinense on bacterially-expressed human hexokinase isoform 2 for anti-dengue drug design
by: Asman, Nur Atikah, et al.
Published: (2020) -
Virtual screening for potential inhibitors of human hexokinase II for the development of anti-dengue therapeutics
by: Tanbin, Suriyea, et al.
Published: (2021) -
Enhanced expression and purification strategy for recombinant bacterially-expressed human hexokinase II
by: Ahmad Fuad, Fazia Adyani, et al.
Published: (2021) -
Elucidating the analogues of 3-bromopyruvate (3-BP) as inhibitors against human hexokinase II for the development of anti-dengue drugs
by: Tanbin, Suriyea, et al.
Published: (2019)